# Consideration of Comorbidities and Multimorbidity in Dementia While Designing Clinical Trials

Friday, July 25, 2025 | 1-5 p.m.
Westin Harbour - Pier 9 — Toronto, Canada
All times are in Eastern Standard Time
*In-person attendance only*

## Overview

This workshop is designed to teach participants how to design clinical trials taking into consideration existing underlying comorbid conditions and also what factors need to be considered from a regulatory perspective. It will: Teach the participants how to design clinical trials while taking into account the impact of the existing comorbid conditions. Teach participants on how to formulate observational studies in cohorts with comorbidities and multimorbidity and analytical methods to be used to account for these.

## Organizing Committee

- Vidyani Suryadevara, PhD

## Target Audience

This ISTAART immersive workshop is designed for individuals at an intermediate level in Administration, Care & Support, Clinical Practice, and Research.

## Learning Objectives

1. Design Clinical Trials taking into consideration comorbidities and multimorbidity
2. Understand the policy frameworks regulating interventions in different countries

## Registration

Educational workshops are offered for in-person attendance only. Workshops require a separate registration fee in addition to AAIC full conference registration, or they may be purchased as stand-alone events. Visit alz.org/AAIC.

ALZHEIMER'S® ASSOCIATION | AAIC 25

**Agenda : July 25th, 2025 | 1:00 pm - 5:00 PM**

| Time | Session Details | Speakers and Moderator |
|---|---|---|
| 12:00 - 1:00 pm | Lunch<br>*(Westin Metropolitan Ballroom)* | |
| 1:00-1:05 PM | Introduction | |
| 1:05-1.55 PM | Globalizing dementia prevention through clinical trial Insights Across Ethnicities and Health Complexities | Chi Udeh-Momoh |
| 1.55-2.25 PM | Insights on comorbidities and multimorbidity in dementia from observational studies | Lucy Stirland |
| 2.25-2.55 PM | Leveraging AI to analyze and interpret large datasets in the context of comorbidities and multimorbidity | Mackenzie Hofford |
| 2.55-3.15 PM | AI to decipher comorbidities and multimorbidity in electronic health records | Judith Harrison |
| 3:15-3:25 PM | **Break** | |
| 3:25-4:10 PM | Panel discussion about pharmacovigilance and regulatory affairs considerations while designing clinical trials | Maria Mora Pinzon<br>Michael Jan |
| 4:10-4:55 PM | Round table discussion of participants to come up with an example of study designs taking into | Vidyani Suryadevara |

| | | |
|---|---|---|
| | consideration what they have learned. | |
| 4:55-5:00 PM | Closing Remarks | Vidyani Suryadevara |